In our established GIST-IR cells, RTK phosphorylation arrays revealed the activation of tyrosine kinase receptors and their downstream targets, despite treatment with high concentrations of imatinib (Figure 1C, 1D, Supplementary Figure 1), which enable GIST-IR cells to resist imatinib cytotoxicity. The gene discussed is NTRK1; the disease is gastrointestinal stromal tumor.